GlassScriptPhysician profile
Ruth L Bailey
NPI 1659845139
$6,456.14
in general payments reported to CMS, 2019-2025
25 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $1,264 · 2023: $1,972 · 2024: $1,312 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,812 · Education: $114 · Travel and Lodging: $18.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,812.33 |
| Education | $114.26 |
| Travel and Lodging | $18.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.87 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $746.75 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $651.57 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $619.95 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $451.87 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $438.94 | 2021-2025 | Caplyta |
| Alkermes, INC. | $404.74 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $378.21 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $323.58 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $313.53 | 2022-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $300.95 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $204.35 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $195.28 | 2022-2024 | Perseris, Sublocade |
| Sunovion Pharmaceuticals INC. | $108.39 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $107.34 | 2022-2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $86.93 | 2022-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $81.54 | 2025 | Jornay Pm |
| Corium, LLC | $80.66 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $65.96 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $48.07 | 2023 | |
| Braeburn INC. | $28.88 | 2024-2025 | Brixadi |
| Almatica Pharma LLC | $23.04 | 2022 | |
| Exact Sciences Corporation | $15.41 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $15.16 | 2021 | |
| Noven Therapeutics, LLC | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.